Knopp NeuroSciences Receives FDA Fast Track Designation for KNS-760704 in ALS
9/2/2009 10:19:30 AM
More...
|
Knopp NeuroSciences to Present Phase 2 Results of KNS-760704 in ALS
8/11/2009 10:10:53 AM
More...
|
European Commission Awards Orphan Designation to Knopp NeuroSciences' KNS-760704 in ALS
3/10/2009 9:17:00 AM
More...
|
Knopp NeuroSciences Completes Series B2 Financing, Raising Total Capitalization to $27 Million
11/19/2008 6:20:40 AM
More...
|
Knopp NeuroSciences Initiates Phase 2 Study of KNS-760704 in Amyotrophic Lateral Sclerosis
4/7/2008 9:15:39 AM
More...
|
Knopp NeuroSciences Completes First Series B Financing of $10 Million
1/22/2008 8:32:02 AM
More...
|
Knopp NeuroSciences Presents Results of Phase 1; Ascending Single-Dose Study of KNS-760704
12/3/2007 11:34:27 AM
More...
|
Knopp NeuroSciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
10/15/2007 8:26:02 AM
More...
|
Cheryl Fossum Graham Joins Knopp NeuroSciences as Head of Regulatory and Development Strategy
10/3/2007 8:22:43 AM
More...
|
Knopp NeuroSciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
9/24/2007 7:42:25 AM
More...
|
|